Status:
UNKNOWN
Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients
Lead Sponsor:
Aarhus University Hospital
Collaborating Sponsors:
Roche Pharma AG
Conditions:
Lung Cancer
ALK Gene Mutation
Eligibility:
All Genders
18+ years
Brief Summary
Circulating tumor DNA can be used to monitor the treatment effect and identify developing resistance mutations during ALK directed TKI treatment.
Detailed Description
The purpose and objectives of the non-interventional study with primary data collection is * To determine if monitoring the amount of translocated DNA in the blood reflects alectinib treatment effect...
Eligibility Criteria
Inclusion
- Patients with ALK translocated metastatic NSCLC, treated with alectinib as 1st line therapy in routine clinical practice
- Written (personally dated and signed) informed consent
Exclusion
Key Trial Info
Start Date :
June 19 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 30 2025
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04708639
Start Date
June 19 2019
End Date
June 30 2025
Last Update
February 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aarhus University Hospital
Aarhus, Denmark, 8200